Biochip News: Breaking Biochip News, Comments and Articles. - Page: 3

Expression Analysis Announces 2013 Grant Program

Expression Analysis (EA), a Quintiles company today announced a grant program that provides scientists with leading-edge products and services to advance genomics research. In the fifth year of EA’s grant program, EA and Illumina will award two grant winners fully-funded exome and RNA sequencing services along with array-based methylation analysis as par...

Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013

PHILADELPHIA and REHOVOT, Israel, April 2, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that two posters related to the Company's microRNA-based diagnostic assays will be featured at the American Association for Cancer Research (AACR) Annual Meeting 2013, to be held April 6-10 at the Walter E. Washing...

New Cancer Research Microarray Detects CNVs and LOH on a Single Chip

A novel, optimized cytogenetic cancer research microarray system enables reliable, simultaneous detection of both copy number variations and loss...

Idera Announces Clinical Development Progress in Its Autoimmune Diseases Program

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that it has completed dosing in its Phase 1 trial of IMO-8400 in healthy subjects. In addition, the Company announced that its protocol for a Phase 2 study of IMO-8400 in patients with psoriasis has received “no objection” clearance from the Competent Authority of the Netherlands. IMO-8400 is a...

Rosetta Genomics Announces Acceptance for Publication of Kidney Cancer microRNA Diagnostic Manuscript by Molecular Oncology

PHILADELPHIA and REHOVOT, Israel, April 1, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that a manuscript regarding the development and validation of the Company's microRNA-based diagnostic assay for the classification of renal cell tumors has been accepted for publication by M...

SQI Diagnostics and Algorithme Pharma Provide Update on Multiplex Heparin Immunogenicity Assay

SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI”), and Algorithme Pharma (“Algorithme”) today announced that they have completed the multiplexed proof of concept assay targeted at immunogenicity testing of hepa...

Affymetrix Signs Contract With UK Biobank to Genotype 500,000 UK Individuals in the Largest Ever Study of Genetic and Environmental Factors in Disease and Personalized Medicine

Affymetrix, Inc. (NASDAQ: AFFX) today announced that it has signed a contract with UK Biobank to genotype 500,000 DNA samples donated by UK residents as part of a prospective epidemiological study of complex diseases that are of great relevance to public health. Affymetrix’

Ingenuity Systems IPA Provides Researchers with Genomic Insights Suggesting that Physical Activity Does Not Slow Muscle Aging

REDWOOD CITY, Calif., March 21, 2013 /PRNewswire/ -- Ingenuity® Systems, a leading provider of biomedical information and analysis solutions, today announced that its IPA technology was instrumental in elucidating a network of genetic drivers for aging. The networks determined, among other things, that muscle age was not primarily related to the biology of physical activity. The research...

OriGene Technologies Raises $21.3 Million in Series C Funding

ROCKVILLE, Md., March 21, 2013 /PRNewswire/ -- OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications, announced the completion of a $21.3 million Series C financing led by Qiming Venture Partners and Kleiner Perkins Caufield Byers China.  OriGene's previous investor IDG-Accel also participated in this round.  "We are pleased with...

Global Biochips and Microarrays 2013 Market Report

Dublin, Ireland (PRWEB) March 19, 2013 This report is an analysis of biochip/microarray markets based on technologies and applications. The report starts with a description of technologies as a basis for estimation of markets. Technologies include...

Aqua Gen and Center for Integrative Genomics (CIGENE) Collaborate With Affymetrix on a Salmon Genotyping Array to Achieve the World’s First High-Density View of the Marker Patterns in the Atlantic Salmon

Aqua Gen, a member of the Erich Wesjohann (EW) Group GmBH and Center for Integrative Genomics (CIGENE) at the Norwegian University of Life Sciences (UMB) in collaboration with

Greenwood Genetic Center Selects Cartagenia BENCHlab NGS, CNV Solutions for Clinical Data Analysis

BOSTON and GREENWOOD, S.C., March 19, 2013 /PRNewswire/ -- Cartagenia, the world leader in providing genetic labs and clinicians software-based workflow support for variant assessment, lab reporting, and integration of diagnostic knowledge-bases, announced today that it has signed a license agreement for its BENCHlab NGS and CNV solutions with South Carolina-based Greenwood Genetic Center, a non-p...

Vermillion Appoints Bruce A. Huebner to Chairman of the Board

AUSTIN, Texas, March 19, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, has appointed Bruce A. Huebner as chairman effective March 18, 2013. He succeeds James S. Burns, who will continue to serve on the board of directors. Huebner's appointment represents an important step in the execution of the company...

Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis

Cancer Genetics, Inc. Selected By Gilead Sciences, Inc. ...

Comprehensive, biomarker-based patient profiling will help risk stratification, improve trial efficacy and provide biomarker driven insight regarding patient targeting and potential outcomes Rutherford, NJ, USA, March 12, 2013 / B3C newswire / - Cancer Genetics, Inc. (CGI) announces that it has been chosen by Gilead Sciences Inc. (Gilead) to provide clinical trial services and molecular profiling...

Precision Therapeutics Announces Topline Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian Cancer using Personalized Chemotherapy Diagnostic ChemoFx®

Precision Therapeutics, Inc., a life science company that develops and markets personalized medicine products for individualizing cancer care, today announced results from a nine-year, multi-center, blinded prospective clinical study which demonstrated statistically significant improvement in overall survival and progression free survival in 262 patients w...

Cellular Dynamics Announces Presentations at the Society of Toxicology's 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development

MADISON, Wis., March 8, 2013 /PRNewswire/ -- Cellular Dynamics International, Inc. (CDI), a leading commercial producer of human induced pluripotent stem cell (iPSC) lines and tissue cells for drug discovery, safety, stem cell banking and cellular therapeutics, today announced scientific presentations at the Society of Toxicology's 52nd Annual Meeting (SOT), March 10 to 14 in San Antonio, that dem...

Affymetrix Names GenoSplice as Its Preferred Data Analysis Service Provider Increasing Accessibility for Bioinformatics in Genomic Research

Affymetrix, Inc. (NASDAQ:AFFX) announced a co-marketing agreement today naming GenoSplice, Inc. as its preferred data analysis service provider for the new

Kinexus Identifies Over 966,000 Phosphorylation Sites in the Human Proteome

Prediction of over 45 million protein kinase-substrate interactions now available at PhosphoNET website VANCOUVER, March 6, 2013 /PRNewswire/ - Kinexus Bioinformatics Corporation, a world-leader in molecular intelligence research, announced a major upgrade in its PhosphoNET KnowledgeBase (www.phosphonet.ca) for the study of cell communication systems. This open-access website now features d...

Accelerate Diagnostics, Inc. Names Frank J. M. ten Brink to Board of Directors

TUCSON, Ariz., March 6, 2013 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), a developer of automated diagnostic systems for same-shift identification and antibiotic resistance testing of bacterial and fungal pathogens, announced today that Frank J.M. ten Brink has been appointed to its board of directors. Mr. ten Brink has more than 16 years of finance, accounting and m...

New Comprehensive Chromosome Screening Program at Pacific Fertility Center Refines Embryo Selection, Improves Pregnancy Rates

San Francisco, CA (PRWEB) March 06, 2013 Comprehensive Chromosome Screening (CCS) helps reduce multiple pregnancies and the risks that accompany them. It allows selection of high-quality embryos for transfer, which not only improves implantation...

A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells

Obesity Makes Fat Cells Act Like They're Infected

HOUSTON, March 5, 2013 /PRNewswire-USNewswire/ -- The inflammation of fat tissue is part of a spiraling series of events that leads to the development of type 2 diabetes in some obese people. But researchers have not understood what triggers the inflammation, or why. In Cell Metabolism this month (cover), scientists from The Methodist Hospital report fat cells themselves are at least partly to bl...

Cancer Genetics, Inc. Receives Regulatory Approvals for MatBA®-DLBCL, A Proprietary Microarray Test for the Diagnosis, Prognosis, and Patient Risk Stratification of Non-Hodgkin Lymphoma

Cancer Genetics, Inc. (CGI), a leader in oncology-focused personalized medicine, today announced it has received CLIA and New York State approvals for clinical use of its proprietary mature B-cell neoplasm array or MatBA® (patent 13/475,034) for diffuse large B-cell lymphoma. MatBA®-DLBCL will assist clinicians in the diagnosis and prognosis of DLBCL....

Aushon Biosystems Thrives with Increasing Demand for Personalized Medicine

With a range of products and services driving the development of personalized medicine, Aushon Biosystems has appointed Thomas Mac Mahon, former president and CEO of Laboratory Corporation of America® Holdings (LabCorp®), to its board of directors. The expansion of its board builds on Aushon’s recent momentum as it is poised for significant growth in 2...